Board Member
Johnson & Johnson (JNJ)Equibles does not estimate personal net worth.
Get an email with a short summary when Johnson & Johnson publishes a filing, an earnings call transcript or a press release.
Get JNJ alertsJoaquin Duato is recorded as Board Member at Johnson & Johnson (JNJ) since January 3, 2022 and CEO at Johnson & Johnson (JNJ). The proxy statement of Johnson & Johnson reports total compensation of $13,805,292 for Joaquin Duato in fiscal 2021, including a base salary of $1,030,000. Disclosed compensation is on record for 5 fiscal years. Joaquin Duato has spoken on 18 earnings calls and 2 other investor events across 1 company, most recently for Johnson & Johnson on October 13, 2026. Johnson & Johnson is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Johnson & Johnson includes J. Wolk (CFO), D. E. Pinto (Board Member), Daniel Pinto (Board Member) and 7 others.
“Our strong performance in the third quarter reinforces our confidence in 2026 as a year of accelerated growth and impact for Johnson & Johnson. In Q3, we reported analyst consensus, an increased sequential growth compared to the second quarter.”
“So there's been a lot of progress in Johnson & Johnson since 2023. First, we have a more focused portfolio today. We have three focus areas in innovative medicine, oncology, immunology, and neuroscience, and then three focus areas also on medical technology, vision, surgery, and cardiovascular.”
“We said 2026 would be a year of accelerated growth and impact for Johnson & Johnson and with our Q2 bid on the top and bottom line and raised guidance, we are delivering.”
“So all investors were thinking, is Johnson & Johnson going to be able to grow through the Stellara biosimilars? And we did. We grew mid-single digit. We exceeded expectations.”
“Our associated schedule would be a year. You can see we are delivering on that promise of the year. We delivered operational sales growth, innovation, higher med need, and high growth.”
2022-01-03–present
Drug Manufacturers - General · Healthcare
CEO, Board Member
2022-01-03–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Johnson & Johnson (JNJ) | Vice Chairman of the Executive Committee | $1,030,000 | $13,805,292 |
| 2020 | Johnson & Johnson (JNJ) | Vice Chairman of the Executive Committee | $1,021,538 | $15,625,003 |
| 2019 | Johnson & Johnson (JNJ) | Vice Chairman of the Executive Committee | $969,615 | $13,419,302 |
| 2018 | Johnson & Johnson (JNJ) | Vice Chairman of the Executive Committee | $934,046 | $9,283,960 |
| 2017 | Johnson & Johnson (JNJ) | Vice Chairman of the Executive Committee | $897,254 | $19,359,308 |
